The Zhitong Finance App learned that CMB International released a research report saying that maintaining the “buy” rating of Yunkang Group (02325) is expected to increase revenue by 78.3% in 2022. Revenue in 2023 is the same as 2022, with a target price of HK$21.39. The company's unaudited revenue for the first three quarters increased 90.9% year-on-year to 2.33 billion yuan, reaching the annual revenue forecast of 85.6%. It mainly benefited from the rapid growth of diagnostic and testing services provided by the core business to the medical consortium. This business segment increased 143.6% year-on-year in the first three quarters, making it one of the fastest growing business segments.

According to the report, since for leading hospitals, co-building laboratories can help them expand their scope of services and increase revenue. For other member hospitals within the medical consortium, building a laboratory enhances their testing capabilities and helps gain the trust of more surrounding residents. Therefore, this co-construction model is a good fit for the current needs of implementing hierarchical diagnosis and treatment. The number of laboratories built by the company has increased rapidly, adding 110 in the first three quarters, bringing the total number of households to 385. At the same time, the revenue of the single firm also continued to rise. The average unaudited revenue for the first three quarters reached 2.7 million yuan.